Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
74 hedge funds and large institutions have $25.6M invested in Zynerba Pharmaceuticals, Inc in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 26 closing their positions.
9% more call options, than puts
Call options by funds: $9.62M | Put options by funds: $8.82M
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
4% less funds holding
Funds holding: 77 → 74 (-3)
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
27% less capital invested
Capital invested by funds: $35.3M → $25.6M (-$9.68M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.06M |
| 2 |
Millennium Management
New York
|
+$1.02M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$784K |
| 4 |
Squarepoint
New York
|
+$685K |
| 5 |
Jane Street
New York
|
+$653K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.06M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.15M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.9M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.67M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.03M |
ZYNE Hedge Fund Activity: Q2 2020 in Review
74 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2020, worth a combined $25.6M — down 27% from $35.3M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ZYNE and 25 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 18 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $3.06M. The largest seller was BlackRock, cutting an estimated $5.06M.
- 74 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2020, down from 77 in Q1 2020.
- Funds reported $25.6M of Zynerba Pharmaceuticals, Inc stock for Q2 2020, down 27% quarter-over-quarter.
- 25 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2020 and 26 closed out, a net change of -1 holder.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2020 was Ikarian Capital, an estimated $3.06M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2020 was BlackRock, an estimated $5.06M sold.
Based on aggregated 13F filings for Q2 2020.